Kaitlyn D’Onofrio

DocwireNews

According to a study, canagliflozin was superior to placebo in reducing serum urate concentration in type 2 diabetes (T2D) patients with a history of <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/no-change-in-prevalence-of-gout-and-hyperuricemia/">gout</a>.&ldquo;Sodium glucose co-transporter 2 inhibitors have been shown to reduce serum urate concentration. The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program integrated data from two similarly designed, [randomized], double-blind, placebo-controlled trials (CANVAS and CANVAS-Renal) assessing the cardiovascular and renal safety of canagliflozin compared with placebo in patients with type 2 diabetes,&rdquo; the researchers wrote. &ldquo;In this post-hoc analysis, we aimed to investigate the effect of canagliflozin compared with placebo on gout in the CANVAS Program.&rdquo;The research was published in <a href="https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(19)30078-5/fulltext">The Lancet Rheumatology</a>. The CANVAS program randomized T2D patients who had an increased cardiovascular disease risk to either canagliflozin (100 mg or 300 mg) or placebo. For this analysis, canagliflozin was compared to placebo in terms of the effect on serum urate concentration through mixed linear models, and the presence of a <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/rheum-round-up-exercises-for-joint-pain-pills-over-pt-for-knee-oa-and-more/">gout flare-related adverse event</a> (AE) or initiation of a gout drug was evaluated through Kaplan-Meier analysis with Cox proportional hazards models, used to calculate a hazard ratio (HR) and 95% confidence intervals (CIs).A total of 10,142 patients were included in this analysis. The mean age (SD) at baseline was 63 (8) years, more than a third of patients (n = 3,633, 36%) were female, mean serum urate concentration was 348.9 (95.5) &mu;mol/L, and 5% of patients (n = 471) had gout history. Patients were followed for a mean (SD) 3.6 (2.0) years.Patients who received canagliflozin had a mean serum urate concentration level &minus;23&middot;3 &mu;mol/L (95% CI, &ndash;25.4 to &ndash;21.3 &mu;mol/L) lower compared to placebo patients&mdash;a 6.7% serum urate reduction (percentage difference, &ndash;6.7%; 95% CI, &ndash;7.3% to &ndash;6.1%). Gout flare occurred in 80 patients during follow-up, and 147 initiated a drug for gout. The canagliflozin patients were less likely to experience a gout flare or require gout treatment compared to the placebo group (HR=0.53; 95% CI, 0.40&ndash;0.71; P&lt;0.0001).&ldquo;The proportional reduction for gout flare adverse events (2&middot;0 patients with an event per 1000 patient-years in the canagliflozin group vs 2&middot;6 patients with an event per 1000 patient-years in the placebo group; 0&middot;64, 95% CI 0&middot;41&ndash;0&middot;99; p=0&middot;046) was similar in size to that for commencement of a drug for gout (3&middot;3 vs 5&middot;4 patients with an event per 1000 patient-years; 0&middot;52, 0&middot;38&ndash;0&middot;72; p&lt;0&middot;0001) and hyperuricaemia (1&middot;8 vs 2&middot;5 patients with an event per 1000 patient-years; 0&middot;59, 0&middot;37&ndash;0&middot;93; p=0&middot;023),&rdquo; the researchers added.The study authors recommended that a future study be conducted dedicated specifically to evaluate the impact of sodium glucose co-transporter 2 inhibition on gout.

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Latest News

Canagliflozin Reduces Gout Flares in T2D Patients

Rheumatology

According to a study, canagliflozin was superior to placebo in reducing serum urate concentration in type 2 diabetes (T2D) patients with a history of gout. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe